GENETIC VARIABILITY IN COLORECTAL NEOPLASIA

$0P50FY2002CANIH

University Of Arizona, Tucson AZ

Investigators

Linked publications & trials

Paper 30277270 Paper 30246144 Paper 29374343 Paper 29369407 Paper 28792646 Paper 28370655 Paper 27928057 Paper 27761517 Paper 27658891 Paper 27657647 Paper 27517467 Paper 27090199 Paper 26918875 Paper 26758693 Paper 26693680 Paper 26633584 Paper 26512205 Paper 26396545 Paper 26193421 Paper 26108564 Paper 26018967 Paper 25995376 Paper 25888489 Paper 25646492 Paper 25622809 Paper 25605447 Paper 25594431 Paper 25561511 Paper 25487746 Paper 25410163 Paper 25355685 Paper 25221625 Paper 25204413 Paper 25187227 Paper 25031429 Paper 24990812 Paper 24939212 Paper 24926433 Paper 24846720 Paper 24791633 Paper 24700753 Paper 24681952 Paper 24587040 Paper 24238056 Paper 24184097 Paper 24152931 Paper 24042167 Paper 23949159 Paper 23940317 Paper 23878224 Paper 23860400 Paper 23850380 Paper 23793224 Paper 23780911 Paper 23754630 Paper 23737330 Paper 23722544 Paper 23718880 Paper 23693020 Paper 23633488 Paper 23613623 Paper 23601132 Paper 23530065 Paper 23466814 Paper 23340449 Paper 23280667 Paper 23251002 Paper 23247939 Paper 23239438 Paper 23232971 Paper 23228309 Paper 23179792 Paper 23094077 Paper 23000383 Paper 22928902 Paper 22912394 Paper 22907422 Paper 22892665 Paper 22891866 Paper 22818162 Paper 22773549 Paper 22711542 Paper 22692860 Paper 22691117 Paper 22690182 Paper 22648715 Paper 22580577 Paper 22558260 Paper 22554971 Paper 22457825 Paper 22434430 Paper 22382881 Paper 22353936 Paper 22301112 Paper 22273698 Paper 22144504 Paper 22126696 Paper 22122766 Paper 22116705 Paper 22079017

Abstract

DESCRIPTION (provided by applicant): The translational goal of this project is to develop simple blood tests to predict colon cancer risk and to tailor therapy for colorectal intraepithelial neoplasia (IEN). Diagnosis of colon cancer at an early stage continues to be problematic, and response to treatment is limited in late stage colon cancer. Better measures of risk will contribute to colon IEN prevention or earlier detection. Earlier detection combined with methodologies to predict response to therapy will decrease colon cancer incidence and mortality. The hypothesis to be tested in this proposal is that the risk of colorectal cancer is influenced by genetic variability affecting the expression/function of the adenomatous polyposis coli (APC) tumor suppressor gene and/or APC modifier genes, such as ornithine decarboxylase (ODC). Measures of this genetic variability may be prognostic and/or predictive factors for colorectal IEN. To test this hypothesis, four specific aims are proposed. First, we will measure specific mutations in the APC tumor suppressor gene in colorectal adenomas from participants in colon cancer prevention trials. Second, we will measure germline polymorphism frequencies in codon 1822 of APC. We will determine associations between genetic variability in APC with dietary factors and adenoma recurrence in this patient group. Third, we will measure the genetic variability in the c-myc-dependent region of the ODC promoter in groups at risk for colorectal IEN, and determine whether polymorphisms are associated with adenoma recurrence. Finally, we will ascertain the functional significance of these polymorphisms in intestinal carcinogenesis. Future studies will measure variability in other downstream mediators of APC. These other mediators include networks regulating polyamine and arachidonic acid metabolism. Since these pathways are targets for IEN therapy (e.g., DFMO, NSAIDs), genetic variability in these pathways may be predictive factors for therapeutic response to treatment.

View original record on NIH RePORTER →